Managers

Connecticut Innovations backs FallCall Solutions

Connecticut-based FallCall Solutions, a creator of a personal emergency assistant app for elderly people and caregivers on the Apple ecosystem, has secured an undisclosed amount of funding. The investor was Connecticut Innovations.

Accolade snags $50 mln

Accolade, an on-demand healthcare concierge company, has secured $50 million in funding. Andreessen Horowitz, Carrick Capital Partners, Madrona Venture Group and McKesson Ventures led the round with participation from investors that included Cross Creek Advisors and Madera Technology Partners.

AngelPad raises $35 mln toward third venture fund

Seed-stage accelerator AngelPad has raised $35 million toward a $50 million third venture fund, according to a filing with the SEC.

Spotify investors, observers mull benefits of direct listing versus the risks

IPO market sets strong pace in Q1, but VC proceeds fall

CDPQ commits $20 mln to Indian tech growth fund

Caisse de dépôt et placement du Québec (CDPQ) has made a US$20 million commitment to Fundamentum's debut growth fund. The target is US$100 million. Fundamentum Partnership-Fund I will focus on investing in India-based consumer and enterprise technology startups. The fund is expected to invest up to an average of US$15 million per company. Along with providing capital to the growth fund, CDPQ will explore making direct investments in portfolio companies. Fundamentum is based in Bangalore.

ZhenFund targets $190 mln for fifth fund

Beijing-based ZhenFund is raising a fifth venture fund, Zhen Partners Fund V, targeted at $190 million, according to a regulatory filing.

USVP targets $300 mln for 12th fund

U.S. Venture Partners is seeking to raise $300 million for its 12th fund, according to an SEC listing. The Silicon Valley-based venture firm invests in information technology and healthcare.

Tempest Therapeutics hauls in $70 mln Series B

San Francisco-based Tempest Therapeutics, a biotechnology company, has closed $70 million in Series B financing. The investors included Versant Ventures, F-Prime Capital Partners, Quan Capital, Lilly Asia Ventures, Foresite Capital and Eight Roads Ventures.

Genprex goes public

Austin, Texas-based Genprex Inc, a developer of immunogene therapy for non-small cell lung cancer, has raised $6.4 million for its IPO after pricing its 1.28 million shares at $5 per share. The stock began trading March 29, 2018 on the NASDAQ under the ticker symbol "GNPX." Network 1 Financial Securities Inc was the sole bookrunner. Genprex's pre-IPO backers include Inception Capital Management.